# Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

> **NCT02167035** · PHASE4 · COMPLETED · sponsor: **Cornerstone Health Care, PA** · enrollment: 43 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Combigan Two Times Daily (BID)
- **DRUG:** Simbrinza Three Times Daily (TID)

## Key facts

- **NCT ID:** NCT02167035
- **Lead sponsor:** Cornerstone Health Care, PA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167035, "Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02167035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*